Cargando…
The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis
Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease (CVD). Treatment with tumor necrosis factor inhibitors improves both joint symptoms associated with RA and also CVD risk. This exploratory analysis of a phase 4 study evaluated changes in metabolic risk factor...
Autores principales: | Deodhar, Atul, Bitman, Bojena, Yang, Yue, Collier, David H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118390/ https://www.ncbi.nlm.nih.gov/pubmed/27704313 http://dx.doi.org/10.1007/s10067-016-3422-7 |
Ejemplares similares
-
Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy
por: Hobbs, Kathryn, et al.
Publicado: (2015) -
Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports
por: Hooper, Michele, et al.
Publicado: (2013) -
Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007) -
Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000) -
Safety of etanercept in elderly subjects with rheumatoid arthritis
por: Lurati, Alfredomaria, et al.
Publicado: (2010)